A phase I, randomized, open label, four arm, two period, two 2x2, crossover, drug interaction study to assess steady-state plasma amprenavir and phenytoin pharmacokinetics following administration of fosamprenavir 700mg BID [twice daily] + ritonavir 100mg BID + phenytoin 300mg QD [once daily], fosamprenavir 700mg BID + ritonavir 100 mg BID, phenytoin 300mg QD in healthy adult subjects

Trial Profile

A phase I, randomized, open label, four arm, two period, two 2x2, crossover, drug interaction study to assess steady-state plasma amprenavir and phenytoin pharmacokinetics following administration of fosamprenavir 700mg BID [twice daily] + ritonavir 100mg BID + phenytoin 300mg QD [once daily], fosamprenavir 700mg BID + ritonavir 100 mg BID, phenytoin 300mg QD in healthy adult subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Apr 2007

At a glance

  • Drugs Amprenavir (Primary) ; Fosamprenavir; Phenytoin; Ritonavir
  • Indications Epilepsy; HIV infections; Trigeminal neuralgia
  • Focus Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 04 Apr 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top